Biotech Values

[kcalt]

Dew <In the HCV arena, the report covers no new ground beyond the potential competition from VRTX’s VX-950 and the newfound risk posed by the Telbivudine dose reduction (the action that caused IDIX to drop by 30% on March 24). I’m considerably less worried about VX-950 than PJ is because: a) The VX-950 data are very early; b) VX-950 may not be suitable for once-daily dosing; and c) As a protease inhibitor, VX-950 could eventually complement Telbivudine in an all-oral (no interferon) cocktail.
>

Do you mean Valopcitibine? NM283 or what not is being re-dosed, not the HBV drug...